NCT07062848 - An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems. | Biotech Hunter

Enrollment

1,500,000

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

AI Toolkit for ATTR-CM Diagnosis

An artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE)

Trial Locations (11)

10029

Mount Sinai, New York

22903

University of Virginia School of Medicine, Charlottesville

27710

Duke Health, Durham

29425

Medical University of South Carolina (MUSC) Health, Charleston

48202

Henry Ford Health, Detroit

75390

UT Southwestern Medical Center, Dallas

77030

Houstin Methodist, Houston

94143

University of California - San Francisco (UCSF) Health, San Francisco

97224

Providence Health, Tigard

98195

University of Washington Medicine, Seattle

06519

Yale New Haven Health System, New Haven